Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement
June 23, 2014 at 08:06 AM EDT
Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and ...
